EE9800080A - (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid - Google Patents

(Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid

Info

Publication number
EE9800080A
EE9800080A EE9800080A EE9800080A EE9800080A EE 9800080 A EE9800080 A EE 9800080A EE 9800080 A EE9800080 A EE 9800080A EE 9800080 A EE9800080 A EE 9800080A EE 9800080 A EE9800080 A EE 9800080A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
furanones
methylsulfonyl
phenyl
cyclooxygenase
Prior art date
Application number
EE9800080A
Other languages
English (en)
Other versions
EE03969B1 (et
Inventor
Yves Gauthier Jacques
Belley Michel
Grimm Erich
Leblanc Yves
Li Chung-Sing
Therien Michel
Black Cameron
Lau Cheuk-Kun
Prasit Petpiboon
Roy Patrick
Original Assignee
Merck Frosst Canada & Co. / Merck Frosst Canada & Cie.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602939.2A external-priority patent/GB9602939D0/en
Priority claimed from GBGB9605645.2A external-priority patent/GB9605645D0/en
Application filed by Merck Frosst Canada & Co. / Merck Frosst Canada & Cie. filed Critical Merck Frosst Canada & Co. / Merck Frosst Canada & Cie.
Publication of EE9800080A publication Critical patent/EE9800080A/et
Publication of EE03969B1 publication Critical patent/EE03969B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Seasonings (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EE9800080A 1995-10-13 1996-10-09 (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid EE03969B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US537195P 1995-10-13 1995-10-13
GBGB9602939.2A GB9602939D0 (en) 1996-02-13 1996-02-13 (Methylsulfony)phenyl-2-(5h)-furanones as cox-2 inhibitors
US1163796P 1996-02-14 1996-02-14
GBGB9605645.2A GB9605645D0 (en) 1996-03-18 1996-03-18 (Methylsulfonyl)phenyl-2-(5H)- furanones as cox-2 inhibitors
PCT/CA1996/000682 WO1997014691A1 (en) 1995-10-13 1996-10-09 (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors

Publications (2)

Publication Number Publication Date
EE9800080A true EE9800080A (et) 1998-10-15
EE03969B1 EE03969B1 (et) 2003-02-17

Family

ID=27451401

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800080A EE03969B1 (et) 1995-10-13 1996-10-09 (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid

Country Status (39)

Country Link
EP (1) EP0863891B1 (et)
JP (2) JP3337476B2 (et)
KR (1) KR100354940B1 (et)
CN (1) CN1203066C (et)
AT (1) ATE229515T1 (et)
AU (1) AU703871B2 (et)
BG (1) BG63391B1 (et)
BR (1) BR9611015A (et)
CA (1) CA2233178C (et)
CO (1) CO4770965A1 (et)
CZ (1) CZ295764B6 (et)
DE (2) DE122005000010I2 (et)
DK (1) DK0863891T3 (et)
DZ (1) DZ2103A1 (et)
EA (1) EA000795B1 (et)
EE (1) EE03969B1 (et)
ES (1) ES2187675T3 (et)
HK (1) HK1016980A1 (et)
HR (1) HRP960458B1 (et)
HU (1) HU222785B1 (et)
IL (1) IL123699A (et)
IS (1) IS2148B (et)
LU (1) LU91145I2 (et)
MX (1) MX9802836A (et)
MY (1) MY141773A (et)
NL (1) NL300175I2 (et)
NO (1) NO321042B1 (et)
NZ (1) NZ319090A (et)
PE (1) PE17198A1 (et)
PL (1) PL188918B1 (et)
PT (1) PT863891E (et)
RO (1) RO119884B1 (et)
RS (1) RS49885B (et)
SA (1) SA96170405B1 (et)
SK (1) SK282639B6 (et)
TR (1) TR199800585T2 (et)
TW (1) TW426679B (et)
UA (1) UA57002C2 (et)
WO (1) WO1997014691A1 (et)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
JP2001514668A (ja) * 1997-03-14 2001-09-11 メルク フロスト カナダ アンド カンパニー Ｃｏｘ−２阻害薬としての酸素連結部を有する（メチルスルホニル）フェニル−２−（５ｈ）−フラノン類
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
JP3516658B2 (ja) * 1997-09-24 2004-04-05 メルク エンド カムパニー インコーポレーテッド Ｃｏｘ−２のインヒビターとして有用な３−アリールオキシ，４−アリールフラン−２−オンの製造方法
FR2770131A1 (fr) * 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
GB2330833A (en) * 1997-10-29 1999-05-05 Merck & Co Inc PREPARATION OF 4-(4-Methylsulfonylphenyl)-2-furanones USEFUL AS COX-2 INHIBITORS
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
EP1028951A1 (en) * 1997-10-30 2000-08-23 Merck Frosst Canada Inc. Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors
FR2771005B1 (fr) * 1997-11-18 2002-06-07 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
JP2002506024A (ja) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
US6136804A (en) 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.
JP2002528435A (ja) * 1998-10-27 2002-09-03 メルク エンド カムパニー インコーポレーテッド メチルチオフェニルヒドロキシケトンの合成
AU767811B2 (en) * 1999-04-14 2003-11-27 Pacific Corporation 4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors
DK1090915T3 (da) 1999-10-08 2009-07-13 Merial Sas Polymorphic B form af 3-(cyclopropylmethoxy)-4--4-(methylsulfonyl)phenyl- 5,5-dimethyl-5H-furan-2-on
FR2799462B1 (fr) * 1999-10-08 2004-05-28 Merial Sas Procede de preparation d'inhibiteurs cox-2
MXPA02004366A (es) 1999-11-05 2002-11-07 Astrazeneca Ab Derivados de quinazolina como inhibidores vegf.
EP1104758B1 (en) 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
DE60018792T2 (de) 1999-12-03 2006-01-26 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
TR200302047T4 (tr) 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
ATE234299T1 (de) 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
AU3653301A (en) * 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
DE60204823T2 (de) 2001-07-05 2005-12-29 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonyl Pyrazole als entzündungshemmende/analgetische Mittel
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
CN1309717C (zh) * 2003-06-03 2007-04-11 李小虎 4－芳基－5h－噻吩－2－酮衍生物、其制法和用途
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
DE602005013116D1 (de) 2004-12-23 2009-04-16 Glaxo Group Ltd Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
AU2006280953B2 (en) * 2005-08-19 2013-01-24 Emisphere Technologies, Inc. Cyclopropyl compounds and compositions for delivering active agents
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
EP1878717A1 (en) 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2062880A1 (en) * 2007-11-22 2009-05-27 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
US8933132B2 (en) 2011-01-19 2015-01-13 Convergence Pharmaceuticals Limited Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
KR102137180B1 (ko) * 2012-09-21 2020-07-24 로드아일랜드하스피틀 암 치료를 위한 베타-하이드록실라제의 억제제
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
CN104803956A (zh) * 2015-03-06 2015-07-29 江苏天和制药有限公司 非罗考昔的一种合成方法
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
EP3609877B1 (en) 2017-04-14 2020-12-23 Cosma S.p.A. Process for the synthesis of firocoxib
CN108178724B (zh) * 2017-12-22 2020-09-11 四川大学 化合物的制备方法
CN110240537B (zh) * 2019-05-22 2022-06-21 成都阿奇生物医药科技有限公司 一种茚氧乙酸类化合物及其制备方法和用途
CN110452198B (zh) * 2019-09-03 2021-03-26 山东鲁抗舍里乐药业有限公司 一种非罗考昔的制备方法
CN110452199B (zh) * 2019-09-03 2021-03-30 山东鲁抗舍里乐药业有限公司 一种非罗考昔的制备方法
DE102019214427A1 (de) 2019-09-23 2021-03-25 Multivac Marking & Inspection Gmbh & Co. Kg Etikettierer mit Montageeinrichtung für Andrückelement
CN110746390B (zh) * 2019-11-14 2022-12-30 中国科学技术大学 制备5-甲酰基-2-呋喃甲酸酯的方法
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
CN113248458B (zh) * 2021-05-27 2022-09-27 陕西省煤田地质集团有限公司 一种α-羰基酰胺化合物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2206978A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors

Also Published As

Publication number Publication date
MY141773A (en) 2010-06-30
PE17198A1 (es) 1998-04-16
HUP9802506A3 (en) 1999-06-28
CO4770965A1 (es) 1999-04-30
NL300175I1 (nl) 2005-04-01
JP2001199954A (ja) 2001-07-24
CA2233178A1 (en) 1997-04-24
JP4068802B2 (ja) 2008-03-26
HUP9802506A2 (hu) 1999-05-28
IS2148B (is) 2006-10-13
NL300175I2 (nl) 2005-05-02
NZ319090A (en) 2000-01-28
HRP960458A2 (en) 1998-04-30
SK45098A3 (en) 1998-12-02
DZ2103A1 (fr) 2002-07-22
PL188918B1 (pl) 2005-05-31
IS4695A (is) 1998-03-20
NO321042B1 (no) 2006-03-06
AU7123696A (en) 1997-05-07
EA199800290A1 (ru) 1998-10-29
SA96170405B1 (ar) 2006-08-22
UA57002C2 (uk) 2003-06-16
WO1997014691A1 (en) 1997-04-24
DE122005000010I1 (de) 2005-06-23
ATE229515T1 (de) 2002-12-15
DE69625374D1 (en) 2003-01-23
EP0863891B1 (en) 2002-12-11
RO119884B1 (ro) 2005-05-30
IL123699A (en) 2002-03-10
CZ295764B6 (cs) 2005-10-12
HU222785B1 (hu) 2003-10-28
AU703871B2 (en) 1999-04-01
RS49885B (sr) 2008-08-07
CA2233178C (en) 2003-12-23
LU91145I9 (et) 2018-12-28
KR19990064265A (ko) 1999-07-26
PT863891E (pt) 2003-03-31
YU54896A (sh) 1999-07-28
SK282639B6 (sk) 2002-10-08
PL326203A1 (en) 1998-08-31
JPH11500146A (ja) 1999-01-06
NO981628L (no) 1998-05-27
CN1203066C (zh) 2005-05-25
EE03969B1 (et) 2003-02-17
TW426679B (en) 2001-03-21
DE69625374T2 (de) 2003-09-11
HRP960458B1 (en) 2003-08-31
LU91145I2 (fr) 2005-05-09
CN1200119A (zh) 1998-11-25
MX9802836A (es) 1998-09-30
BG63391B1 (bg) 2001-12-29
TR199800585T2 (xx) 1998-07-21
IL123699A0 (en) 1998-10-30
JP3337476B2 (ja) 2002-10-21
EP0863891A1 (en) 1998-09-16
HK1016980A1 (en) 1999-11-12
BG102425A (en) 1999-06-30
BR9611015A (pt) 1999-09-14
CZ110198A3 (cs) 1998-09-16
DE122005000010I2 (de) 2006-03-16
ES2187675T3 (es) 2003-06-16
EA000795B1 (ru) 2000-04-24
DK0863891T3 (da) 2003-03-17
NO981628D0 (no) 1998-04-08
KR100354940B1 (ko) 2003-01-24

Similar Documents

Publication Publication Date Title
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
IL110031A0 (en) Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
DE69816047D1 (en) (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
MY119407A (en) 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
ECSP961893A (es) (metil sulfonil) fenil -2-(5h)- furanomas como inhibidores de cox - 2''
TH51723B (th) (เมทิลซัลโฟนิล) ฟีนิล-2-(5h)-ฟูราโนน ที่เป็นตัวขัดขวาง cox-2

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

AA1Y Spc filed

Free format text: PRODUCT NAME: PREVICOX-FIROCOXIB; REG NO/DATE: EU/2/04/045/001 13.09.2004 EU/2/04/045/002 13.09.2004 EU/2/04/045/003 13.09.2004 EU/2/04/045/004 13

Spc suppl protection certif: C20050001

Filing date: 20050301

FG1Y Spc granted

Free format text: PRODUCT NAME: PREVICOX-FIROCOXIB; REG NO/DATE: EU/2/04/045/001 13.09.2004 EU/2/04/045/002 13.09.2004 EU/2/04/045/003 13.09.2004 EU/2/04/045/004 13

Spc suppl protection certif: C20050001 00006

Filing date: 20050301

Extension date: 20250301

KB4A Valid patent at the end of a year

Effective date: 20051231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name